In a further step blurring the line between biological machines and man-made machines, R.I.-based MultiCell Technologies Inc. has been granted a U.S.
patent on its Sybiol synthetic bio-liver device. Apparently the device incorporates an immortalized liver cell line into an implantable device.
A business unit of Warwick, R.I.-based MultiCell Technologies Inc. has been granted a U.S. patent on its Sybiol synthetic bio-liver device. The
patent includes more than 40 claims to the device and methods for its use in the purification of a patient’s bodily fluids.
San Diego-based Xenogenics Corp 's synthetic bio-liver device was redesigned to use the MultiCell's immortalized human liver cell lines. The Sybiol
bio-liver is a device designed to support patients who are waiting for liver transplants and are suffering from episodic liver disease caused by
hepatitis, alcoholism or cancer, or from burn or toxic shock syndrome or other liver trauma.
Jerry Newmin, MultiCell's CEO, said the company intends to file additional patents covering further improvements to the Sybiol device and its
MultiCell provides non-tumorigenic functional hepatic (liver) cells and cell lines to pharmaceutical companies for induction studies and toxicity
screening for drug discovery.
Please visit the link provided for the complete story.
Discoveries such as this are certainly good new for those suffering and waiting for liver transplants. An invention such as this signifies that we
probably are not too far away from regenerating entire organs using cell lines. The problem of using immortalized cell lines (cancerous) will have to
be eliminated, and certain other aspects such as contact inhibition and growing the complete organ need to be addressed, but this is a step towards
being able to regenerate organs completely.
This content community relies on user-generated content from our member contributors. The opinions of our members are not those of site ownership who maintains strict editorial agnosticism and simply provides a collaborative venue for free expression.